The clinical data verified the association of the identified genes (i.e., KIF2C, CCNA2, NDC80, KIF11, KIF23, ANLN, and CENPM) with the targeted therapy response and prognosis of glioma patients (Fig 5). The gene discussed is ANLN; the disease is central nervous system cancer.